3. Summary of treatments.

ATC group, trial	Substance	Daily dose	Maximum recommended dose	Treatment duration	Sample size calculation	Participants per group (n)
Butylpyrazolidin
Grevsten 1975	Phenylbutazone (Butazolidin) IM day 1; phenylbutazone (Butazolidin Alka) orally day 2 to 4	0.6 g IM day 1, 0.6 g day 2 to 4 by mouth, 0.3 g day 5 to 14	No longer approved for human use	14 days	No	36
Weber 1980	Phenylbutazone (Butazolidin Alka)	600 mg day 1 to 3, 300 mg day 4 to 5	No longer approved for human use	5 days	No	59
Radin 1968	Phenylbutazone	600 mg day 1 to 2, 300 to 800 mg day 3 to 8	No longer approved for human use	8 days	No	25
Acetic acid derivatives
Goldie 1968a	Indomethacin	75 mg	225 mg	14 days	No	25
Herrmann 2009	Diclofenac	100 mg day 1 and 5; 150 mg day 2 to 4	150 to 200 mg	4 days	50 per group	57
Dreiser 2001b	Diclofenac	150 mg	150 to 200 mg	14 days	150 per group	162
Kanayama 2005	Diclofenac vs active treatment	75 mg	150 to 200 mg	14 days	20 per group	20
Oxicams
Dreiser 2001a (placebo‐controlled trial)	Meloxicam 7.5/15 mg	7.5/15 mg	15 mg	7 days	150 per group	171/181
Dreiser 2001b (diclofenac‐controlled trial)	Meloxicam 7.5/15 mg	7.5/15 mg	15 mg	14 days	150 per group	164/163
Weber 1993	Piroxicam	100 mg day 1 to 2, 20 mg day 3 to 14	20 mg	14 days	No	120
Herrmann 2009	Lornoxicam	24 mg day 1; 16 mg day 2 to 4; 8 mg day 5	16 mg	5 days	50 per group	57
Propionic acid derivative
Braun 1982	Ketoprofen vs active treatment	200 mg IM day 1 to 3, 300 mg orally + supp day 4 to 8	200 (max 300) mg	9 days	No	17
Fenamates, coxibs, or others
No studies	‐‐	‐‐	‐‐	‐‐	‐‐	‐‐

ATC: Anatomical Therapeutic Chemical
 IM: intramuscular